Business · 27/06/1997
FDA Approves New Treatment for Dogs with Pituitary-Dependent Hyperadrenocorticism
The Food and Drug Administration (FDA) is updating its animal drug regulations to reflect the approval of a new treatment for dogs with pituitary-dependent hyperadrenocorticism, following a submission by Deprenyl Animal Health, Inc. for the use of selegiline hydrochloride tablets.
Original source language: Federal Register — Food and Drug AdministrationOpen original release →